Proprietary Expert Insight Drives Successful Investment for Private Equity Firm
Techspert’s platform surfaced niche molecularly imprinted polymer specialists whose evidence-backed insights on scalability, IP, and market demand helped turn a tight-deadline diligence into a confident investment decision.
The Challenge
A European private equity firm was assessing whether to invest in companies developing molecularly imprinted polymer (MIP) technology. To form a reliable view of both technical feasibility and market potential, they needed first-hand insight from specialists with experience in academic innovation and commercialization across the US and EU5 markets. Securing this range of perspectives - within the tight due diligence timeline - wasn’t possible through traditional expert panels.
The customer asked Techspert to connect them with specialists who had:
- Deep expertise in molecularly imprinted polymer technology
- Experience developing MIP from an academic perspective
- Experience commercialising MIP-based products in life sciences, such as bioprocessing, diagnostics, and therapeutics
- Executive-level insight into supporting third-party organizations (e.g. biotech firms) in implementing MIP technologies—whether in product development or R&D
While some vendors might struggle with this level of specificity, Techspert’s platform is built for exactly this kind of challenge.
Our Approach
Techspert’s platform scanned billions of public data points to identify a shortlist of subject matter experts who matched the investor’s exact brief - spanning academic research, product development, and third-party implementation of MIP technologies. Each expert profile was vetted by our delivery team before introduction, ensuring every conversation delivered decision-critical depth, not generic commentary. Recruits included:
A Professor of Nanobiotechnology who is also the head of the university molecular imprinting technology research group, and author of a book on the same subject, which reviews the present position of the technology and potential future trends.
An Executive VP of Business Development with over 25 years of experience in life science, pharma, and biotech industries, experienced in developing the service business for nanoMIPs in sensing, purification, separations, analysis, and diagnostics.
The Outcome
Through a focused series of calls, the investor secured evidence-backed answers on technical scalability, competitive IP, and near-term revenue opportunities. With that clarity, the firm moved forward with confidence - closing its investment in an MIP platform company knowing that both risks and growth levers had been thoroughly vetted.
Connect to the right experts today.
Let us find the expertise you need
